AR048971A1 - Composicion para sensibilizacion a otra terapia anticancerosa y/o mitigacion de un efecto colateral de otra terapia anticancerosa mediante el tratamiento con un compuesto anticanceroso activado por gst - Google Patents
Composicion para sensibilizacion a otra terapia anticancerosa y/o mitigacion de un efecto colateral de otra terapia anticancerosa mediante el tratamiento con un compuesto anticanceroso activado por gstInfo
- Publication number
- AR048971A1 AR048971A1 ARP050102064A ARP050102064A AR048971A1 AR 048971 A1 AR048971 A1 AR 048971A1 AR P050102064 A ARP050102064 A AR P050102064A AR P050102064 A ARP050102064 A AR P050102064A AR 048971 A1 AR048971 A1 AR 048971A1
- Authority
- AR
- Argentina
- Prior art keywords
- gst
- therapy
- optionally substituted
- compound
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 11
- 238000011319 anticancer therapy Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000000694 effects Effects 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 206010070834 Sensitisation Diseases 0.000 title 1
- 230000000116 mitigating effect Effects 0.000 title 1
- 230000008313 sensitization Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 abstract 7
- 241000124008 Mammalia Species 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000001235 sensitizing effect Effects 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 241000219198 Brassica Species 0.000 abstract 1
- 235000003351 Brassica cretica Nutrition 0.000 abstract 1
- 235000003343 Brassica rupestris Nutrition 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 229940000635 beta-alanine Drugs 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 238000001815 biotherapy Methods 0.000 abstract 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 abstract 1
- OJLHWPALWODJPQ-QNWVGRARSA-N canfosfamide Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 OJLHWPALWODJPQ-QNWVGRARSA-N 0.000 abstract 1
- 229950000772 canfosfamide Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 238000009126 molecular therapy Methods 0.000 abstract 1
- 235000010460 mustard Nutrition 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57279004P | 2004-05-20 | 2004-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048971A1 true AR048971A1 (es) | 2006-06-14 |
Family
ID=34970551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102064A AR048971A1 (es) | 2004-05-20 | 2005-05-19 | Composicion para sensibilizacion a otra terapia anticancerosa y/o mitigacion de un efecto colateral de otra terapia anticancerosa mediante el tratamiento con un compuesto anticanceroso activado por gst |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20050261202A1 (https=) |
| EP (1) | EP1755632A1 (https=) |
| JP (1) | JP2007538105A (https=) |
| KR (1) | KR101174685B1 (https=) |
| CN (1) | CN1953762B (https=) |
| AR (1) | AR048971A1 (https=) |
| AU (1) | AU2005245004B2 (https=) |
| BR (1) | BRPI0511296A (https=) |
| CA (1) | CA2566850A1 (https=) |
| MX (1) | MXPA06013375A (https=) |
| TW (1) | TW200538149A (https=) |
| WO (1) | WO2005112973A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
| ES2293834B1 (es) | 2006-07-20 | 2009-02-16 | Consejo Superior Investig. Cientificas | Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas. |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| AU2006350707A1 (en) * | 2006-11-08 | 2008-05-15 | Chongxi Yu | Transdermal delivery systems of peptides and related compounds |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| KR101449579B1 (ko) * | 2007-04-14 | 2014-10-13 | 써던 리서취 인스티튜트 | 화학요법제 및 방사선을 결합한 종양 치료방법 |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| US20100310661A1 (en) * | 2007-07-16 | 2010-12-09 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
| CN101903029B (zh) * | 2007-11-02 | 2012-09-26 | Zio医药肿瘤学公司 | 使用有机砷化物的联合治疗 |
| ES2332557B1 (es) | 2007-12-04 | 2011-02-02 | Universidad Autonoma De Madrid | Huella genomica para el pronostico de la evolucion de adenocarcinoma colorectal. |
| ES2332167B1 (es) | 2007-12-04 | 2010-10-25 | Universidad Autonoma De Madrid | Empleo de trefoil factor-family 3 (tff3) en el pronostico de sujetos diagnosticados con cancer colorectal. |
| CA2715348A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and bevacizumab to treat colorectal cancer |
| CA2717915A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
| ES2338843B1 (es) | 2008-07-02 | 2011-01-24 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Huella genomica de cancer de mama. |
| EP2169078A1 (en) | 2008-09-26 | 2010-03-31 | Fundacion Gaiker | Methods and kits for the diagnosis and the staging of colorectal cancer |
| PL2427475T3 (pl) | 2009-05-08 | 2021-07-19 | Techfields Biochem Co., Ltd. | Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami |
| SG10201810806UA (en) * | 2009-06-05 | 2019-01-30 | Cavion Inc | Interlaced method for treating cancer or a precancerous condition |
| EP2542155B1 (en) | 2010-03-01 | 2015-11-04 | TAU Therapeutics LLC | Method for imaging a disease |
| US20120251496A1 (en) * | 2011-03-31 | 2012-10-04 | Telik, Inc. | Ezatiostat for treating multiple myeloma |
| US20120288554A1 (en) * | 2011-05-12 | 2012-11-15 | Telik, Inc. | Canfosfamide monotherapy for treating multiple myeloma |
| WO2013092960A1 (en) | 2011-12-22 | 2013-06-27 | Fundacion Gaiker | Methods and kits for the diagnosis of colorectal cancer |
| JP6280546B2 (ja) | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| WO2015194522A1 (ja) | 2014-06-17 | 2015-12-23 | 日東電工株式会社 | アポトーシス誘導剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5556942A (en) * | 1991-04-29 | 1996-09-17 | Terrapin Technologies, Inc. | Glutathione S-transferase-activated compounds |
| US5767147A (en) * | 1995-04-21 | 1998-06-16 | The Regents Of The University Of California | Inhibition of glutathione transferase by haloenol lactones |
| DK0831877T3 (da) | 1995-06-07 | 2005-02-14 | Telik Inc | Metabolske virkninger af visse glutathionanaloge |
| US5880097A (en) * | 1996-01-04 | 1999-03-09 | Terrapin Techologies, Inc. | Tethered prodrugs |
| US6281223B1 (en) * | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
-
2005
- 2005-05-10 TW TW094115086A patent/TW200538149A/zh unknown
- 2005-05-19 BR BRPI0511296-6A patent/BRPI0511296A/pt not_active IP Right Cessation
- 2005-05-19 CN CN2005800158989A patent/CN1953762B/zh not_active Expired - Fee Related
- 2005-05-19 WO PCT/US2005/017960 patent/WO2005112973A1/en not_active Ceased
- 2005-05-19 MX MXPA06013375A patent/MXPA06013375A/es active IP Right Grant
- 2005-05-19 CA CA002566850A patent/CA2566850A1/en not_active Abandoned
- 2005-05-19 JP JP2007527521A patent/JP2007538105A/ja active Pending
- 2005-05-19 EP EP05752058A patent/EP1755632A1/en not_active Withdrawn
- 2005-05-19 US US11/133,833 patent/US20050261202A1/en not_active Abandoned
- 2005-05-19 AR ARP050102064A patent/AR048971A1/es not_active Application Discontinuation
- 2005-05-19 AU AU2005245004A patent/AU2005245004B2/en not_active Ceased
-
2006
- 2006-12-08 KR KR1020067025870A patent/KR101174685B1/ko not_active Expired - Fee Related
-
2007
- 2007-10-15 US US11/872,662 patent/US8207121B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005112973A1 (en) | 2005-12-01 |
| EP1755632A1 (en) | 2007-02-28 |
| KR20070012542A (ko) | 2007-01-25 |
| CA2566850A1 (en) | 2005-12-01 |
| AU2005245004A1 (en) | 2005-12-01 |
| US20080166428A1 (en) | 2008-07-10 |
| MXPA06013375A (es) | 2007-03-01 |
| KR101174685B1 (ko) | 2012-08-16 |
| CN1953762A (zh) | 2007-04-25 |
| JP2007538105A (ja) | 2007-12-27 |
| US20050261202A1 (en) | 2005-11-24 |
| CN1953762B (zh) | 2012-04-25 |
| US8207121B2 (en) | 2012-06-26 |
| BRPI0511296A (pt) | 2007-12-04 |
| AU2005245004B2 (en) | 2011-08-04 |
| TW200538149A (en) | 2005-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048971A1 (es) | Composicion para sensibilizacion a otra terapia anticancerosa y/o mitigacion de un efecto colateral de otra terapia anticancerosa mediante el tratamiento con un compuesto anticanceroso activado por gst | |
| WO2023078021A1 (en) | Bcma monoclonal antibody and the antibody-drug conjugate | |
| ES2706063T3 (es) | Agonistas del receptor de NMDA y usos del mismo | |
| CN101590229B (zh) | 一种gst活化的抗癌化合物与另一种抗癌疗法的复合癌症疗法 | |
| ES3008466T3 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| AR043859A1 (es) | Inhibidores de serina proteasas, particularmente de la proteasa ns3-ns4a del hcv | |
| PE20212329A1 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cancer | |
| RU2013144368A (ru) | Пролекарства действующих веществ гетероциклическими линкерами | |
| AR038863A1 (es) | Uso de un inhibidor de garft y/o de aicarft y de un agente antitoxico para preparar un medicamento para destruir selectivamente celulas mtap-deficientes de un mamifero | |
| AR044513A1 (es) | Inhibidores de serina proteasas, particularmente de la proteasa ns3-ns4a del hcv | |
| ES2178632T3 (es) | Compuestos de benzoquinazolina farmaceuticamente activos. | |
| AR039562A1 (es) | Compuestos oxo-azabiciclicos | |
| ES2385087T3 (es) | Procedimientos para tratar trastornos relacionados con sustancias | |
| ES2676198T3 (es) | Derivados amino-quinoxalina para el tratamiento de enfermedades neurodegenerativas | |
| Saydjari et al. | Effects of cyclosporin A and α-difluoromethylornithine on the growth of hamster pancreatic cancer in vitro | |
| CA2461348A1 (en) | [[2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain | |
| MX2020007908A (es) | Derivados de aminoacidos que contienen un grupo disulfanilo como un inhibidor de endopeptidasa neutra (nep) y aminopeptidasa n (apn) para la prevencion y el tratamiento del dolor del nervio trigemino. | |
| WO2022084325A1 (en) | Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer | |
| Vasin et al. | Radioprotective properties of indralin combined with cystamine and mexamine | |
| YAMAMOTO et al. | Action of reserpine on the lethal effect of cytotoxic alkylating agents | |
| ATE505483T1 (de) | Derivate des biologisch aktiven peptids vapeehptllteaplnpk | |
| UY28119A1 (es) | Nuevos derivados que contienen fosforo | |
| AR049312A1 (es) | Derivados de alquil piperazinas utiles como inhibidores de la recaptacion del neurotrasmisor de monoamina | |
| AR036080A1 (es) | Compuesto de 1-(2´-aminoaril)-2-cianopirrolidina o derivados de aplicacion en tratamientos que perjudican la tolerancia de glucosa o para la diabetes tipo 2, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento | |
| TH68401A3 (th) | สารยับยั้งฟาร์นีซิลโปรตีนทรานส์เฟอเรสที่มีคุณสมบัติกระตุ้นความไวต่อรังสีในร่างกาย |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |